11) TMTI
Abstract
Multiagent Broad Spectrum Medical Countermeasures - This effort will advance experimental broad-spectrum drug candidates at a Technology Readiness Level (TRL) 4 through the Technology Development phase. This includes further preclinical evaluation (as necessary) and initiation and completion of Phase I clinical studies, where a new drug is introduced into humans and early evidence is gathered on drug safety. Approved performers who have had their Investigational New Drug (IND) applications accepted by the Food and Drug Administration (FDA) will initiate Phase 1 clinical trials and other studies necessary to support a Milestone B decision and progress toward a New Drug Application (NDA) with the FDA.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2012
- Source ID
- d92b54bd7bfdd6b5008a6f7ec8f3086b